DX6-25070-37902
2 vaccinations
1 coded response
15 check-ins
1 free-text entry
1 call case
- Sex
- Female
- Age at first dose
- 61-65
- ZIP prefix
- 184 / PA
- Registered
- 2020-12-23
- Relationship
- Self
- Race
- White
- Ethnicity
- Hispanic or Latino
Timeline
-
2020-12-23
Registered in v-safe
-
2020-12-23
Dose 1 — Pfizer-BioNTech
- 2020-12-23
- 2020-12-28
- 2020-12-29
- 2020-12-30
- 2021-01-06
- 2021-01-13
-
2021-01-14
Dose 2 — Pfizer-BioNTech
- 2021-01-21
- 2021-01-28
- 2021-02-04
- 2021-02-11
- 2021-02-18
- 2021-02-25
- 2021-04-15
-
2021-07-15
Survey response — 6 months, dose 2MedDRA: Endometrial cancer, Uterine dilation and curettage — Feeling: Good · Get care from a doctor or other healthcare professionalFree text: Symptoms: Diagnosed with endometrial Cancer · Healthcare visit (other): D&CMedDRA releases: 2021-09,2024-11 · check-in free text available
-
2021-07-15
Report sent to call center — 6 months, dose 2Get care from a doctor or other healthcare professional1 call case(s)
- 2021-07-23
- 2022-01-14
Vaccinations
| Dose | Date | Manufacturer | Co-administered |
|---|---|---|---|
| 1 | 2020-12-23 | Pfizer-BioNTech | |
| 2 | 2021-01-14 | Pfizer-BioNTech |
Call center
| Reported | Outcome | VAERS-related outcome |
|---|---|---|
| 2021-07-15 | Unsuccessful |
Free text
Release 9 — 6 months, dose 2
Each entry is dated by the survey it was written in (the CDC re-sent the releases with survey dates in 2025); click a date to see that survey response. The CDC cut some text off at about 250 characters: symptoms in every release, and the other two fields in releases 9-12. Those entries are marked "cut off by CDC".
MedDRA terms by release
| Field | Preferred term | 2021-09 | 2023-04 | 2024-11 |
|---|---|---|---|---|
| HCVO | Uterine dilation and curettage | ✓ | · | ✓ |
| SD | Endometrial cancer | ✓ | · | ✓ |
✓ active code · ○ coded but marked inactive · blank = not in that release